Literature DB >> 27077927

Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.

Andreas Sashegyi1, Yawei Zhang2, Yong Lin1, Polina Binder2, David Ferry2.   

Abstract

Entities:  

Keywords:  VEGFR/VEGF inhibitor; cancer; gastrointestinal perforation; meta-analysis; ramucirumab; risk

Mesh：

Substances：

Year:  2016        PMID： 27077927     DOI： 10.1080/1120009X.2015.1113023

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


× No keyword cloud information.
  4 in total

1.  Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report.

Authors:  Mioko Matsuo; Kazuki Hashimoto; Rina Jiromaru; Takashi Nakagawa
Journal:  J Med Case Rep       Date:  2022-10-22

2.  A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis.

Authors:  Shinya Urakawa; Daisuke Sakai; Yasuhiro Miyazaki; Toshihiro Kudo; Aya Katou; Chiaki Inagaki; Koji Tanaka; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Shuji Takiguchi; Taroh Satoh; Masaki Mori; Yuichiro Doki
Journal:  Surg Case Rep       Date:  2017-12-19

3.  Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation.

Authors:  Asim Haider; Ayesha Siddiqa; Maham Mehmood; Muhammad Adrish
Journal:  Am J Case Rep       Date:  2021-02-18

4.  Bronchobiliary fistula after ramucirumab treatment for advanced gastric cancer: A case report.

Authors:  Hong-Beum Kim; Yong Sub Na; Hee-Jeong Lee; Sang-Gon Park
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.